ZFAND3

Across TCGA pan-cancer cohorts, ZFAND3 mass-spec protein is linked to patient survival in 4 of 34 cancer types, making it a survival-associated ZFAND3 data layer compared with 24 for mass-spec protein and 2 for mutation status.

The strongest signal is observed in lung squamous cell carcinoma (LSCC), where higher ZFAND3 mass-spec protein is associated with better overall survival. In most high-consensus cancer types, elevated ZFAND3 expression acts as an unfavorable survival marker, although some lineages such as LSCC show a favorable association.

LSCC, PDAC, and CCRCC are the cancer types where ZFAND3 mass-spec protein most reproducibly stratifies survival.

mass-spec protein survival associations by lineage

Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.

Lineage	Measure	Split	Stage	AUC1 high	AUC2 low	p	Sampling consensus
LSCC	OS	Tertile	II,III,IV	0.941	0.503	.005	30	view →
PDAC	DFS	Quartile	All	0.473	0.809	.009	13	view →
CCRCC	DFS	Quartile	All	0.708	0.952	.023	9	view →
HNSC	OS	Quartile	II,III,IV	0.645	0.900	.020	5	view →

Pink = unfavorable, green = favorable. Showing the 4 strongest of 4 lineages.

ZFAND3–LSCC (OS)

Open the LSCC breakdown →